CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $4.96M, lower than 95% of all stocks globally
- PositionGross margin is 10.6%, lower than 95% of its Biotechnology peers (median 67.1%)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
940.89BKRW666.19M · vs all stocks (USD)
Revenue (TTM)
7.00BKRW4.96M · vs all stocks (USD)
Beta
0.4210xvs all stocks
52-Week Change
152.50%vs all stocks
Market Capitalization
940.89BKRW666.19M · vs all stocks (USD)
Enterprise Value
903.37BKRW639.62M · vs all stocks (USD)
Price to Book (MRQ)
28.63xvs Biotechnology peers
Enterprise to Revenue
128.97xvs Biotechnology peers
Enterprise to EBITDA
-30.44xvs Biotechnology peers
Gross Margin
10.56%vs Biotechnology peers
Operating Margin
-394.75%vs Biotechnology peers
Return on Assets (TTM)
-33.84%vs Biotechnology peers
Return on Equity (TTM)
-75.49%vs Biotechnology peers
Revenue (TTM)
7.00BKRW4.96M · vs all stocks (USD)
Revenue per Share (TTM)
197.33KRWUpdated Aug 19, 2026Quarterly Revenue Growth
1.10%vs Biotechnology peers
Gross Profit (TTM)
874.16MKRW618.94K · vs all stocks (USD)
EBITDA (TTM)
-29.68BKRW-21.01M · vs all stocks (USD)
Net Income (TTM)
-31.77BKRW-22.50M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.12%vs Biotechnology peers
Operating Cash Flow (TTM)
-31.71BKRW-22.45M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-21.73BKRW-15.38M · vs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
5.15BKRWFY2025 · Dec 31, 2025Revenue
6.98BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
6.05BKRWFY2025 · Dec 31, 2025Gross Profit
929.87MKRWFY2025 · Dec 31, 2025Operating Income
-29.76BKRW-21.07M · vs all stocks (USD)
Pre-tax Income
-31.26BKRWFY2025 · Dec 31, 2025Net Income
-31.26BKRWFY2025 · Dec 31, 2025EBIT
-30.95BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-27.55BKRWFY2025 · Dec 31, 2025Research & Development
21.52BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
3.69BKRWFY2025 · Dec 31, 2025Other Operating Expenses
209.35MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
1.11BKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
310.52MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-31.26BKRWFY2025 · Dec 31, 2025Minority Interests (P&L)
1.21BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-32.17BKRWFY2025 · Dec 31, 2025Free Cash Flow
-32.19BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.04BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-31.26BKRWFY2025 · Dec 31, 2025Stock-based Compensation
931.33MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-801.50MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-348.62MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-693.18MKRWFY2025 · Dec 31, 2025Capital Expenditures
-20.39MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-3.64BKRWFY2025 · Dec 31, 2025Purchase of Investments
-35.60BKRWFY2025 · Dec 31, 2025Sale of Investments
39.75BKRWFY2025 · Dec 31, 2025Other Investing Activity
-10.08BKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.96BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
21.80BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-69.41MKRWFY2025 · Dec 31, 2025Other Financing Charges
-16.71MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
42.95BKRWFY2025 · Dec 31, 2025Shares Outstanding
37.26MSharesUpdated Aug 19, 2026Float Shares
27.50MSharesUpdated Aug 19, 2026% Held by Insiders
25.96%vs all stocks
% Held by Institutions
9.60%vs all stocks
Total Cash (MRQ)
43.62BKRW30.88M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.17KKRWUpdated Aug 19, 2026Total Debt (MRQ)
13.04BKRW9.23M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.3973xvs Biotechnology peers
Current Ratio (MRQ)
19.26xvs Biotechnology peers
Book Value per Share (MRQ)
881.87KRWUpdated Aug 19, 2026Total Assets
61.99BKRW43.89M · vs all stocks (USD)
Total Current Assets
51.59BKRWFY2025 · Dec 31, 2025Total Liabilities
22.80BKRWFY2025 · Dec 31, 2025Total Non-current Assets
10.41BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
18.90BKRWFY2025 · Dec 31, 2025Total Current Liabilities
3.90BKRWFY2025 · Dec 31, 2025Cash Equivalents
21.04BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
21.04BKRWFY2025 · Dec 31, 2025Other Short-term Investments
29.02BKRWFY2025 · Dec 31, 2025Accounts Receivable
536.84MKRWFY2025 · Dec 31, 2025Inventory
46.26MKRWFY2025 · Dec 31, 2025Accounts Payable
336.40MKRWFY2025 · Dec 31, 2025Short-term Debt
297.88MKRWFY2025 · Dec 31, 2025Other Current Liabilities
22.45MKRWFY2025 · Dec 31, 2025Long-term Debt
12.35BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
490.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
18.60BKRWFY2025 · Dec 31, 2025Retained Earnings
-237.86BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
39.19BKRW27.75M · vs all stocks (USD)
Treasury Stock
23.37MKRWFY2025 · Dec 31, 202552-Week Low
9.72KKRWUpdated Aug 19, 202652-Week High
62.90KKRWUpdated Aug 19, 202652-Week Change
152.50%vs all stocks
Beta
0.4210xvs all stocks
50-Day MA
21.31KKRWUpdated Aug 19, 2026200-Day MA
29.55KKRWUpdated Aug 19, 2026Avg 10-Day Volume
249.30KSharesUpdated Aug 19, 2026Avg 30-Day Volume
155.59KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-880.00KRWUpdated Aug 19, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Three Turnover Ratios Elevated
Collects fast, clears inventory fast, and pays suppliers fast too.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 10.6%, lower than 95% of its Biotechnology peers (median 67.1%)Significant
Gross margin: 0.11Industry median: 0.67Industry P5: 0.14Peers compared: 261
Price-to-book is 28.63×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 28.63Industry median: 2.97Industry P95: 23.50Peers compared: 261
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $4.96M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,959,235.597Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Contec Medical Systems Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Yatai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tibet Duorui Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Newland Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
LivsMed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Henan Taloph Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sinotherapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Gyre Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Abclon Inc.
3 interpretationsThree Turnover Ratios ElevatedPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Apact Co. Ltd.
3 interpretationsThree Turnover Ratios ElevatedPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
NHN KCP Corp.
3 interpretationsThree Turnover Ratios ElevatedPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated